Seeing into the Future: Collaborative Care to Maintain Eye Health in Patients with Diabetes

Jointly provided by Postgraduate Institute for Medicine and Novus Medical Education.

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.

Scroll to the Bottom of this Information to Begin this Course

Release date: July 14, 2017

Valid through: July 14, 2018

Specialty: Endocrinology, Diabetology

Topic: Diabetic Retinopathy (DR)

Media: Internet

Estimated Time to Complete Activity: 45 minutes

Target Audience

This activity is intended for primary care clinicians, endocrinologists, diabetes educators and other healthcare professionals who care for patients with diabetes.

Program Overview

Diabetic retinopathy (DR) results from persistently elevated blood sugar levels, which cause the blood vessels that nourish the retina to leak, swell and/or grow abnormally on the surface of the retina. Left untreated, DR can progress and result in moderate-to-severe vision loss. In fact, DR is the leading cause of vision loss among working-age adults in the U.S. A major reason for this lies in both prevalence and awareness, or lack thereof, among patients with diabetes. Research shows that nearly 30% of patients with diabetes have some form of diabetic retinopathy, yet 70% of those with DR are unaware they have eye disease related to their diabetes.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss with patients the impact diabetes has on their eyes
  • Counsel patients on the importance of glycemic control in preventing diabetic eye disease
  • Identify barriers to referral for dilated examinations and treatment among patients, and develop novel approaches to overcome them
  • Discuss with patients treatment options and general therapeutic outcomes for diabetic eye disease
  • Differentiate between eye care specialists and the nature of referrals appropriate to each one

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.


John E. Anderson, MD

Internal Medicine & Diabetes
The Frist Clinic – Nashville, TN

John W. Kitchens, MD

Ophthalmologist & Vitreoretinal Surgeon
Retina Associates of Kentucky – Lexington, KY

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine (PIM) and Novus Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. Anderson
  • Consulting: Merck
  • Consulting & Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Sanofi.
Dr. Kitchens
  • Advisory Board, Consulting and Speakers’ Bureau: Alcon, Alimera, Bayer, Bausch + Lomb, Genentech, Janssen, Optos, Regeneron, Zeiss

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The Novus Medical Education planner, Steven Scrivner, has nothing to disclose.

Instructions for Participation and Credit

There is no fee for this activity.

In order to receive credit, participants must: (1) Read the learning objectives and faculty disclosure; (2) Watch the webcast; (3) Complete the posttest with a passing score of 75% or higher, and (4) Complete the CME evaluation.

Statements of credit will be issued online.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM) and Novus Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.